New treatment approach for kidney scarring by targeting a specific protein
Novel therapeutic strategy for renal fibrosis by targeting RNA-binding protein HuR
This study is exploring a new treatment that targets a protein in the kidneys to help reduce inflammation and scarring, which could improve kidney function and slow down kidney disease for patients dealing with renal fibrosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10831028 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic strategy to combat renal fibrosis, a condition that leads to kidney failure. The approach focuses on targeting a protein called HuR, which plays a crucial role in regulating inflammation and immune responses in the kidneys. By using a specific inhibitor, KH-3, the research aims to reduce kidney inflammation and fibrosis, potentially improving kidney function and slowing disease progression. Patients may benefit from this innovative treatment if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic kidney disease or renal fibrosis.
Not a fit: Patients with acute kidney injury or those without significant renal fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows or stops the progression of kidney disease, improving patient outcomes.
How similar studies have performed: Other research has shown promising results in targeting similar pathways for kidney disease treatment, suggesting potential for success in this approach.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Huang, Yufeng — University of Utah
- Study coordinator: Huang, Yufeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.